The study concludes that the NUTM2A‐AS1/miR‐376a‐3p/PRMT5 axis is critical for the maintenance of oncogenic traits in PCa, highlighting its potential as a target for novel therapeutic strategies. This evidence concerns the gene PRMT5 and posterior cortical atrophy.